HLS
$388M—
Healius
Medical imaging
One of Australia's largest pathology and imaging networks
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$0.0M
Dec 2025 4C
Runway
—Based on Dec 2025 4C
Market Cap
$388M
Burn Rate
$1.0M/qtr
Dec 2025 4C
Shares Outstanding
726M
Pipeline Assets
2
Latest Insights(2)
15 Apr 2026substantial_holderCeasing to be a substantial holder
Ceased·Dimensional Entities
substantial_holderBecoming a substantial holder from MQG
New holder·Macquarie Group Limited·5%
3M Price
HLS.ASX$0.535-43.1% 3M
Low $0.500High $0.950
Pipeline Assets (2)
Lumus ImagingDiagnostic radiology and imaging
ApprovedMontserrat Day HospitalsDay hospital / procedural services
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
Lumus Imaging
Diagnostic radiology and imaging
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Transactions
3 transactionsLast 90dNet Buy
Buys3+3 vs prior
Sells0
Buy Value$87k
warning2 directors bought within 30 days (03-12 – 03-12) — $87k total
$5,0002026-03-12
Substantial Holders (5%+ threshold)
11 noticesINITIALMacquarie Group Limited
5.00%2026-04-15
CEASEDDimensional Entities
CEASEDMacquarie Group Limited and its controlled bodies corporate
INITIAL
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
1 competitor trialPhase 2+ · Non-ASX
Diagnostic Radiology And Imaging1 active trial
1 Ph3
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (2)
FY2026 EBIT target test (~$48M)
UpcomingExpectedarrow_upwardHigh31 Aug 2026
Pathology national operating model — high single-digit EBIT margins
UpcomingExpectedarrow_upwardHigh30 June 2027
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| FY2026 EBIT target test (~$48M) Market questioning whether $48M FY26 EBIT guidance is achievable | other | Expected | arrow_upwardHigh |
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.
Announcements(12)
article
substantial_holderauto_awesome
Becoming a substantial holder from MQG15 Apr 2026
expand_more410KB
article
substantial_holderauto_awesome
Ceasing to be a substantial holder from MQG13 Apr 2026
expand_more156KB